MPS Powered by Eureka

Current Cancer Drug Targets

ISSN: 1568-0096 (Print)
eISSN: 1873-5576 (Online)

Current Cancer Drug Targets aims to cover all the latest and outstanding developments in full spectrum of cancer drug discovery and development, including but not limited to cellular and molecular biology, genomics, proteomics, metabolomics, medicinal chemistry, pharmacology, toxicology, and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes and genes.
Current Cancer Drug Targets publishes original research articles, letters/commentary/perspectives, reviews / mini-reviews, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel drug targets for human anticancer drug discovery continues to grow, this journal has become essential reading for all biomedical and pharmaceutical scientists involved in drug discovery and development. Its scope covers publications related to prevention, diagnosis and treatment of all types of human cancers in various of basic and translational researches, including cancer etiology, signal transduction, biomarker, chemotherapy, hormone therapy, gene therapy, immunotherapy, radiotherapy, immunotherapy and combination therapy, stem cell, tumor environment, metabolism emphasizing on advanced mechanistic investigations.

Special Issues With Active Call for Papers

Submission closes on: Dec 31, 2024
Innovative Cancer Drug Targets: A New Horizon in Oncology

Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but are not limited to, specific mutations, aberrant signaling pathways, tumor microenvironment factors, and immune checkpoints that are pivotal in cancer development and progression. The thematic... see more

Submission closes on: Sep 30, 2024

Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune response are of great importance in clinical oncology. The immune system plays a critical role in oncogenesis and DDR pathways play pivotal role to protect... see more

Submission closes on: Sep 10, 2024
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics

This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing the identification and validation of novel biomarkers. Contributions should explore how single-cell sequencing and spatial transcriptomics provide unique insights into the cellular interactions within the... see more

Submission closes on: Aug 05, 2024
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment

Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. Based on the close relationship between inflammation and cancer progression, targeting inflammation is an important way for improving anti-cancer treatment. A better understanding of the... see more

Submission closes on: Jul 31, 2024
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy

Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers for various cancer types. Additionally, the discovery of potential drug targets through the study of cancer biomarkers has opened up new avenues for targeted cancer... see more